India has announced new regulatory measures targeted at improving biopharmaceutical development and compliance.

Natera, a global leader in cell-free DNA testing, has submitted the first module of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Signatera. Signatera is Natera's personalized and tumor-informed molecular residual disease (MRD) test,

Advent International and Warburg Pincus have successfully completed their acquisition of Baxter International Inc.'s BioPharma Solutions (BPS) business.

Promontory Therapeutics Inc., a clinical-stage biotechnology company specializing in immunogenic small molecule approaches in oncology, has achieved the distinction of being the first international company to gain membership in the Paris-Saclay Cancer Center (PSCC).

A leading biopharmaceutical company in Asia has introduced cutting-edge cold chain technology to enhance vaccine distribution efficiency.

ASEAN health authorities have released new regulations that will significantly impact biologics manufacturing processes across member countries.

Oragenics, Inc. (NYSE American: OGEN) has entered into a significant partnership with Lantern Bioworks, marked by the formalization of a materials transfer agreement. This collaboration follows rigorous testing and validation of biological samples from Oragenics.

Orsini Specialty Pharmacy has been chosen by Amicus Therapeutics as the provider for Pombiliti™ (cipaglucosidase alfa-atga) and Opfolda™ (miglustat), a combination treatment approved for specific patients with late-onset Pompe disease.

Mabwell, an innovative biopharmaceutical company with an entire industry chain, has announced that the first patient has been dosed in a phase Ib/II trial of its novel Nectin-4 targeting ADC (R&D code: 9MW2821) in combination with a PD-1 inhibitor for the treatment of locally advanced or metastatic urothelial carcinoma.

Everest Medicines has received approval from the Taiwan Food and Drug Administration (TFDA) for its New Drug Application (NDA) for XERAVA® (eravacycline).